CTCX - carmellrx.com Real Price to Acquire Entire Company

Brandmark of Carmell Therapeutics (CTCX)

Carmell Corporation (CTCX) operates in the regenerative medicine segment, where it faces intense pressure from industry behemoths and risks of certification delays. Unique patents for plasma materials and strict FDA oversight serve as business safeguards. The share price of illustrated below highlights financial pressure resulting from a strategic shift toward bio-cosmetics and a liquidity shortage.

carmellrx.com (CTCX) - Total Company Value from 07/04/2022 to 10/31/2026

Carmell Corporation (CTCX) - metric breakdowns and financial figures

- current price and projected stock value:
Price Carmell Corp.|CTCX - Analyst Consensus Forecast
- market capitalization statistics:
Market Valuation Carmell|CTCX - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Equity per Share Carmell|CTCX - Company Book Value|Market Capitalization to Net Assets carmellrx.com|CTCX - Company Total Assets
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio Carmell Corporation|CTCX - Long-Term Debt to Capital|Short-Term Debt to Capital carmellrx.com|CTCX - Company Debts|Debt to Net Assets Ratio Carmell|CTCX - Company Long-Term Debt|Company Current Liabilities Carmell|Quick Ratio carmellrx.com
- earnings and valuation multiples indicators:
CTCX - Net Income
Analysis of all company metrics:Carmell Corp.
Brand item of Carmell Corporation

Investors utilize this metric as an objective cost for a full business buyout, eliminating market noise and speculative price fluctuations. The sum of market capitalization and net debt in the enterprise value modeling reflects the actual price of integrating the biotechnological assets of Carmell Corporation (CTCX), which create an innovative environment for tissue regeneration and accelerated healing in aesthetic medicine.

Competitors of Carmell Corporation (CTCX)

Aggregate Business Value ASND (Ascendis Pharma AS)|Madrigal Pharma - Enterprise Value|Corcept Therapeutics Corp (CORT) - Real Price to Acquire Entire Company|RYTM (Rhythm Pharmaceuticals) - Real Price to Acquire Entire Company|Business Value AKRO|Total Company Value Metsera|MoonLake Immunotherapeutics AG - Full Business Value|Enterprise Value CRNX|NAMS (NewAmsterdam Pharma Corp) - Value Adjusted for Debt and Cash|Enterprise Value SLNO (Soleno Therapeutics)|Enterprise Value amicusrx.com FOLD|ETNB - Total Company Value|Value Adjusted for Debt and Cash AGIO (Agios)|Structure Pharma (GPCR) - Total Company Value|Real Price to Acquire Entire Company MiMedx Corp|RZLT (Rezolute, Inc.) - Enterprise Value|Enterprise Value lexpharma.com|Real Price to Acquire Entire Company MBX (MBX Biosciences)|ALT (Altimmune Inc) - Value Adjusted for Debt and Cash|Total Company Value Aardvark Therapeutics Corp AARD|SGMT - Real Price to Acquire Entire Company|BioAge Labs, Inc. - Enterprise Value|Total Enterprise Value biomeafusion.com|QNCX (quincetx.com) - Real Price to Acquire Entire Company|GUTS: Aggregate Business Value|VTVT (vTv Therapeutics, Inc.) - Enterprise Value|Enterprise Value Agape ATP Corp.|Enterprise Value PLUR|Total Company Value SYBX (synlogictx.com)|Total Company Value Lipocine LPCN|Matinas BioPharma Holdings, Inc. (MTNB) - Total Enterprise Value|SPRB - Total Company Value|GLTO: Total Company Value|LUMO: Enterprise Value|ONVO - Company Buyout Price|Total Company Value Radius Recycling